No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TSHA Taysha Gene Therapies
- 3.6800
- +0.0600+1.66%
Close Jun 4 16:00 ET
- 3.7400
- +0.0600+1.63%
Post 19:51 ET
688.23MMarket Cap-4717P/E (TTM)
3.7800High3.5800Low2.24MVolume3.6300Open3.6200Pre Close8.25MTurnover2.10%Turnover RatioLossP/E (Static)187.02MShares3.945052wk High12.78P/B392.87MFloat Cap0.500052wk Low--Dividend TTM106.76MShs Float33.3500Historical High--Div YieldTTM5.53%Amplitude0.5000Historical Low3.6840Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Is Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company?
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
Buy Rating Affirmed: Taysha Gene Therapies Poised for Breakthrough on Pediatric Data and FDA Support
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Athira Pharma (ATHA) and Taysha Gene Therapies (TSHA)
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)
Comments
$Taysha Gene Therapies(TSHA.US$ Reuters· 2 mins ago
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (Rmat) Designation Granted by U.S. FDA for Tsha-102 in Rett Syndrome
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (Rmat) Designation Granted by U.S. FDA for Tsha-102 in Rett Syndrome
1
4
$Taysha Gene Therapies(TSHA.US$ Spinal Delivery Of Taysha's Gene Therapy Shows Promise In Rare Childhood Neurodegenerative Disease
Benzinga· 47 mins ago
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early childhood was well tolerated and showed signs of therapeutic benefit in a Phase 1 trial led by the National Institutes of Health (NIH).
The study was suppo...
Benzinga· 47 mins ago
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early childhood was well tolerated and showed signs of therapeutic benefit in a Phase 1 trial led by the National Institutes of Health (NIH).
The study was suppo...
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg